Navigation Links
Nutrition 21 Announces Fiscal First Quarter 2010 Financial Results

PURCHASE, N.Y., Nov. 4 /PRNewswire-FirstCall/ -- Nutrition 21, Inc. (OTC Bulletin Board: NXXI), the developer and marketer of ingredients and finished products under the Iceland Health®, Chromax®, and Diabetes Essentials®( )brands that help consumers manage blood sugar levels, improve cardiovascular health, enhance memory and reduce chronic joint pain, today announced financial results for the first quarter of fiscal year 2010 ended September 30, 2009.

The Company reported total revenues of $4.6 million for the first quarter ended September 30, 2009, compared to $12.7 million in the corresponding quarter a year ago. Net loss for the first quarter this year was $0.6 million, or $(0.01) per diluted common share, compared to net income of $0.2 million, or $0.00 per diluted common share, in the first quarter a year ago.

The Company's continuing emphasis on controlling its expenses reduced operating expenses by $3.9 million, or 62%, from $6.3 million in the first quarter last year to $2.4 million in the first quarter this year. The reduction in expenses was the primary reason for the Company's $0.4 million operating profit for the first quarter of this fiscal year.

Michael Zeher, president and chief executive officer, said, "While economic conditions continue to be extremely challenging, we are aggressively managing our expenses and, as a result, were profitable on an operating basis in the first quarter. We also continue to work diligently to arrange new financing to replace the current line that we will pay off on November 15, 2009. Moreover, we continue to work with the Iceland Health principals to reach an accommodation on the $2.5 million plus interest that we owe them and secured with the Iceland Health trademark."

"Additionally, in the first quarter we signed a non-binding letter of intent for the sale of certain assets and liabilities of our retail and direct response businesses to a privately-owned company," continued Mr. Zeher. "We will announce the terms of the proposed sale if the transaction proceeds and a binding agreement is signed. Proceeds from the sale of these assets would improve the Company's short-term financial situation, and would allow us to refocus our efforts on growing our consistently profitable ingredients business.

"There are many nutritional products, supplements, pharmaceuticals, and animal feed products that can be enhanced by the addition of our patented ingredients. We look forward to developing these new business opportunities both here in the U.S. and abroad. Accordingly, we're pleased to note that our chromium picolinate product was recently approved for use as an ingredient in the European Union markets.

"In short, we are working to alleviate our current financial situation and to gradually become a profitable company. We plan to grow the business with more focused and streamlined operations, an improved balance sheet, and consistently positive cash flow. "

About Nutrition 21

Nutrition 21, Inc. (OTC BB: NXXI.OB), headquartered in Purchase, NY, is a nutritional bioscience company and the maker of chromium picolinate-based and omega-3 fish oil-based supplements with health benefits substantiated by clinical research. Nutrition 21 holds more than 30 patents for nutrition products and uses. Nutrition 21's portfolio of health and wellness products include: Iceland Health Chromax®, Iceland Health Advanced Memory Formula(TM), Diabetes Essentials(TM), Iceland Health® Maximum Strength Omega-3 and Iceland Health® Joint Relief. The company also manufactures private label supplements and ingredients for third parties. Nutrition 21 distributes its products nationally through more than 29,000 major food, drug and super center retailers as well as internationally. For more information please visit

Safe Harbor Provision

This press release may contain certain forward-looking statements. The words "believe," "expect," "anticipate" and other similar expressions generally identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based largely on the company's current expectations and are subject to a number of risks and uncertainties, including without limitation: the effect of the expiration of patents; regulatory issues; uncertainty in the outcomes of clinical trials; changes in external market factors; changes in the company's business or growth strategy or an inability to execute its strategy due to changes in its industry or the economy generally; the emergence of new or growing competitors; various other competitive factors; and other risks and uncertainties indicated from time to time in the company's filings with the Securities and Exchange Commission, including its Form 10-K/A for the year ended June 30, 2009. Actual results could differ materially from the results referred to in the forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements contained in this press release will in fact occur. Additionally, the company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that may bear upon forward-looking statements.

                                 NUTRITION 21, INC.
                           CONSOLIDATED BALANCE SHEETS
                               (Dollars in thousands)

                                                       September 30, June 30,
                                                            2009        2009
                                                            ----        ----
                                                        (unaudited)  (Note 1)
    Current assets:
       Cash and cash equivalents                            $592      $1,373
       Accounts receivable, net                            2,357       2,752
       Other receivables, net                                 90         516
       Inventories, net                                    3,582       3,878
       Other current assets                                  264         467
    Property and equipment, net                               44          46
    Patents, trademarks and other intangibles, net           750         766
    Goodwill and other intangibles with indefinite lives   3,636       3,636
    Other assets                                           1,116       1,389
                                                           -----       -----
    TOTAL ASSETS                                         $12,431     $14,823
                                                         =======     =======

    Short-term borrowings                                 $3,070      $4,457
    Accounts payable                                       4,068       4,439
    Accrued expenses                                       1,540       2,218
    Deferred income                                          144         361
    Deferred income taxes                                  1,200       1,200

    8% Series J convertible preferred stock subject to
     mandatory redemption                                 13,658      13,218
                                                          ------      ------

              Total liabilities                           23,680      25,893
                                                          ------      ------
    Stockholders' Deficit                                (11,249)    (11,070)
                                                        --------    --------
    TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT          $12,431     $14,823
                                                         =======     =======

                                NUTRITION 21, INC.
                 (in thousands, except share and per share data)

                                                        Three Months
                                                        September 30,
                                                    2009           2008
                                                    ----           ----

    Net sales                                     $4,542        $12,609
    Other revenues                                    94             51
                                                     ---            ---
    Total Revenues                                 4,636         12,660
                                                   -----         ------
    Costs and Expenses

    Cost of Revenues                               1,813          4,745

    Advertising and Promotion                      1,303          5,362

    General and Administrative                       980            798

    Research and Development                          79             80

    Depreciation and Amortization                    105            363
                                                     ---            ---

    Total Costs and Expenses                       4,280         11,348
                                                   -----         ------

    Operating Profit                                 356          1,312

    Interest income (expense), net                  (999)        (1,098)
                                                   -----        -------

    (Loss) income before income taxes               (643)           214

    Income taxes                                      --             --
                                                   -----          -----

    Net (loss) income                              $(643)          $214
                                                  ======           ====

    Basic and diluted (loss) earnings per
     common share                                 $(0.01)         $0.00
                                                 =======          =====

    Weighted average number of common shares
     - basic and diluted                     $72,455,162    $64,134,052
                                             ===========     ==========

        Nutrition 21, Inc.          Lytham Partners, LLC
        Alan Kirschbaum             Joe Diaz, Joe Dorame, Robert Blum
        914-701-4500                602-889-9700

SOURCE Nutrition 21, Inc.

SOURCE Nutrition 21, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. IOM recommends new nutritional requirements for school meal programs
2. Fitness Nutritions Amino Acid Complex Olympic Champion Dara Torres Calls The Best Product Ive Ever Used, Selects TransMedia for PR
3. For Older Adults, Good Nutrition and Exercise Are Key To Staying Healthy & Active
4. Nutrition Still Not A Grade in U.S. Schools: Studies
5. Bariatric Advantage Re- Launches ProMend ABG Designed to Nutritionallly Support Pre and Post Plastic Reconstructive Surgery Patient
6. Compatible Technology International Project to Enhance Child Nutrition and Livelihoods of Rural Families in Malawi and Tanzania
7. Protica Teams With UNFI/Select Nutrition to distribute All-Natural Protein Shot, Proasis
8. Innovative New Book Series Encourages Kids to Go Behind Their Parents' Backs and Listen to Experts on Important Health and Wellness, Education, Personal Finance and Nutrition
9. Senior Living Residences Launches Innovative Nutrition Program to Promote Cognitive Health and Lower the Risk of Alzheimers Disease
10. Frost & Sullivan Cites Arm & Hammer for Excellence in the Dairy Animal Nutrition and Management Market
11. People with type 2 diabetes not meeting important nutritional recommendations
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... ... 2017 , ... HMP , a leader in healthcare events and education, today ... Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & ... award competition recognizes editorial and design excellence across a range of sectors. This year’s ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
Breaking Medicine Technology: